Clinical Trial

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2025-05-22; most recent amendment 2026-01-05.
Status change: Not Yet Recruiting → Recruiting 2025-06-02
Trial Details
NCT Number NCT06999187
Lead Sponsor Dren Bio
Conditions Triple Negative Breast Cancer, HER2-negative Breast Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Castrate Resistant Prostate Cancer, Pancreatic Ductal Adenocarcinoma, Head-and-neck Squamous Cell Carcinoma, Endometrial Cancer +4 more
Enrollment 96 participants
Start Date 2025-06-03
Primary Completion 2027-07 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-07